Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
Ghassan K. Abou-Alfa
Research Funding - Chugai Pharma; Roche
Chia-Jui Yen
No relevant relationships to disclose
Jorge A. Carrasquillo
Research Funding - Chugai Pharma
Chih-Hung Hsu
Consultant or Advisory Role - Chugai Pharma; Roche
Research Funding - Chugai Pharma; Roche
Bolorsukh Gansukh
No relevant relationships to disclose
Jennifer Ma
No relevant relationships to disclose
Ellen Hollywood
No relevant relationships to disclose
Peter J Wan
No relevant relationships to disclose
Yu Yun Shao
No relevant relationships to disclose
Zhong-Zhe Lin
No relevant relationships to disclose
Catherine Frenette
Research Funding - Chugai Pharma
Bert H. O'Neil
Research Funding - Chugai Pharma
Lawrence H. Schwartz
Research Funding - Chugai Pharma
Toshihiko Ohtomo
Employment or Leadership Position - Chugai Pharma
Takayoshi Tanaka
Employment or Leadership Position - Chugai Pharma
Stock Ownership - Chugai Pharma
Ya-Chi Chen
Employment or Leadership Position - Roche
Stock Ownership - Roche
Stacey Ukrainskyj
Employment or Leadership Position - Roche
Stock Ownership - Roche
Leonard Saltz
No relevant relationships to disclose
Reuy-min Lee
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ann-Lii Cheng
Research Funding - Chugai Pharma